Sidmak Laboratories (india) Private Limited

Sidmak Laboratories (India) Private Limited, established in 1983, is a prominent Indian pharmaceutical exporter specializing in the development and manufacturing of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24230GJ1983PTC006157 and is registered with the Registrar of Companies, Ahmedabad. Its registered office is located at S. No. 4662, 4663, and 4779 & 4785, N. H. No. 48, Abrama, P. B. No. 121, Valsad, Gujarat, India, 396001.

Sidmak Laboratories is a private, non-government company with an authorized share capital of ₹50 million and a paid-up capital of ₹18.085 million. The company is unlisted and has been actively engaged in the pharmaceutical sector for over four decades. As of June 2025, Sidmak Laboratories employed over 500 qualified personnel, reflecting its significant presence in the industry.

Sidmak Laboratories operates two state-of-the-art manufacturing facilities in India:

• Valsad Plant: Located in Gujarat, this facility is WHO-GMP certified and specializes in the production of various pharmaceutical formulations, including tablets, capsules, and transdermal drug delivery systems.

• Dehradun Plant: Situated in Uttarakhand, this plant is approved by the US FDA and focuses on the manufacturing of controlled-release tablets, bi-layered tablets, coated and uncoated tablets, enteric-coated tablets, film-coated tablets, hard gelatin capsules, transdermal, and topical patches.

Both facilities are equipped with advanced technology platforms and adhere to stringent quality control measures, ensuring the production of high-quality pharmaceutical products.

Sidmak Laboratories is led by a team of experienced directors:

• Dhananjay Thakorbhai Desai: Director since February 6, 2008.

• Uday Ratilal Shah: Whole-Time Director since April 7, 2010.

• Vinayak Tulsidas Bhalani: Director since September 26, 1996.

These leaders have been instrumental in steering the company towards growth and innovation in the pharmaceutical industry.

Sidmak Laboratories has established a strong presence in several regulated markets:

• United States: The Dehradun facility is approved by the US FDA, enabling the company to export pharmaceutical products to the U.S. market.

• European Union and United Kingdom: While specific regulatory approvals are not detailed, the company's adherence to international quality standards suggests potential market access.

• Australia and Japan: There is no publicly available information regarding regulatory approvals or market access in these regions.

Sidmak Laboratories' compliance with global regulatory standards positions it favorably for expansion into these markets.

Sidmak Laboratories has made strategic inroads into emerging markets:

• Africa and Latin America: The company's export data indicates shipments to these regions, reflecting its growing footprint.

• Southeast Asia: While specific data is limited, the company's global expansion strategy likely includes this region.

The company's adherence to WHO prequalification standards enhances its credibility and facilitates access to these markets.

Sidmak Laboratories demonstrates a diversified geographic strategy:

• Diversification Assessment: The company's export data shows shipments to various regions, indicating a broad market reach.

• Concentration Risk: With a significant portion of exports in the CNS & Psychiatric category, there is a potential concentration risk.

• Strategic Direction: The company's focus on diverse therapeutic categories and global markets suggests a balanced approach to growth.

Sidmak Laboratories' Dehradun facility holds approval from the US FDA, allowing the company to manufacture and export pharmaceutical products to the United States. Specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available.

Sidmak Laboratories' Valsad facility is WHO-GMP certified, ensuring compliance with international quality standards. Specific information regarding EU GMP certificates and EDQM status is not publicly available.

Sidmak Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, facilitating its operations within India. The company's adherence to Indian regulatory standards underscores its commitment to quality and compliance.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Sidmak Laboratories. This absence suggests a favorable regulatory standing.

Sidmak Laboratories operates in a competitive pharmaceutical export market, contending with both domestic and international companies. While specific competitors are not identified, the company's focus on CNS & Psychiatric and Advanced Antibiotics categories positions it in direct competition with firms specializing in these therapeutic areas.

Sidmak Laboratories' key strengths include:

• Regulatory Approvals: FDA approval for the Dehradun facility and WHO-GMP certification for the Valsad plant.

• Product Portfolio: A concentrated portfolio with a strong presence in the CNS & Psychiatric category.

• Manufacturing Capabilities: State-of-the-art facilities capable of producing a wide range of pharmaceutical formulations.

Sidmak Laboratories is strategically positioned as a manufacturer of generic pharmaceutical products, with a focus on CNS & Psychiatric and Advanced Antibiotics categories. The company's adherence to international quality standards and regulatory approvals supports its growth trajectory. Future outlooks may include expanding into new therapeutic areas and markets.

Sidmak Laboratories has a commendable track record in the pharmaceutical industry, with over 40 years of experience. The company's export volume and consistency, as evidenced by 110 shipments valued at $5.5 million USD, reflect its reliability. The absence of regulatory actions further underscores its dependability as a supplier.

Importers should verify the following certifications to ensure product quality and compliance:

• FDA Approval: Confirm the Dehradun facility's FDA approval status.

• WHO-GMP Certification: Verify the Valsad facility's WHO-GMP certification.

• EU GMP Certification: Assess the company's compliance with EU GMP standards.

• ISO Certifications: Review any ISO certifications related to quality management systems.

Importers should undertake the following steps to ensure a thorough evaluation:

• Regulatory Compliance: Verify all relevant certifications and approvals.

• Financial Stability: Review the company's financial statements for the latest fiscal year.

• Product Quality: Assess product samples for quality and compliance with specifications.

• References: Seek feedback from existing clients and partners.

• Supply Chain Reliability: Evaluate the company's logistics and delivery capabilities.

Red flags to watch for include discrepancies in regulatory documents, financial irregularities, and negative feedback from references.